CR-001
Multispecific antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: data expected mid-2027 (GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025), 12 Nov 2026). “Additionally, Kelun initiated multiple Phase 2 clinical studies in China of its trophoblast cell-surface antigen 2 (TROP2)-directed ADC sacituzumab tirumotecan (“sac-TMT”) in combination with CR-001 to evaluate the safety, tolerability, and efficacy in patients with non-small cell lung cancer (“NSCLC”) and other solid tumors, with initial data from NSCLC patients anticipated in mid-2027 (second or third quarter).” Source ↗
Company guidance: data expected mid-2027 (NCT07335497; GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025), 12 Nov 2026). “In mid-2027 (second or third quarter), we plan to share initial standard of care chemotherapy combination data from ASCEND.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ASCEND NCT07335497 · Solid Tumors Registry: NCT07335497 | 1/2 | Dose Escalation - Incidence and nature of dose-limiting toxicities (From the first dose of study drug up until approximately 1 month); Dose Escalation - Characterization of the maximum tolerated dose, if applicable (From the first dose of study drug up until approximately 1 month); All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse events (From the first dose of study drug until 90 days after the last dose of study drug); All parts - Incidence and severity of TEAEs leading to dose modifications (From the first dose of study drug until 90 days after the last dose of study drug); All parts - Incidence and severity of TEAEs leading to treatment discontinuation (From the first dose of study drug until 90 days after the last dose of study drug) 2029-02 | In progress: results expected 1 Feb 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other PD-1 + VEGF drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Solid Tumors: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CR-001: this drug | Stage not on record | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Larotrectinib | Approved | Small molecule | TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions) | Weak signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repotrectinib | Approved | Small molecule | ROS1/NTRK | not yet graded | No reviewed efficacy summary in this indication | |
| Selpercatinib (Retevmo) | Approved | Small molecule | RET | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3(overall) | Multispecific antibody | PD-1 + VEGF | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RC148 | Phase 3(overall) | Multispecific antibody | PD-1 + VEGF | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SCTB14 | Phase 3(overall) | Multispecific antibody | PD-1 + VEGF | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ALG.APV-527 | Phase 1/2 | Multispecific antibody | 4-1BB (CD137) x 5T4 | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Dual-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Tumor antigen menu (TROP2, MSLN, B7-H3, HER2) | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Single-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Personalized, biomarker-guided allogeneic chimeric antigen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Micvotabart Pelidotin | Phase 1/2 | Antibody–drug conjugate | ED-B domain of fibronectin | not yet graded | No reviewed efficacy summary in this indication | |
| Linebacker | —(overall) | Small molecule | PIM kinases (PIM1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| RP3 | Discontinued | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow CR-001 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
February 2029 (1)
Company guidance: data expected mid-2027 (GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025), 12 Nov 2026). “In mid-2027 (second or third quarter), we plan to share initial standard of care chemotherapy combination data from ASCEND.” Source ↗